Open Access

Higher blood aldosterone level in metabolic syndrome is independently related to adiposity and fasting plasma glucose

  • Jui-Kun Chiang1, 2,
  • Chi-Ling Chen2, 3,
  • Feng-Yu Tseng4,
  • Yu-Chiao Chi2,
  • Kuo-Chin Huang5 and
  • Wei-Shiung Yang2, 4Email author
Cardiovascular Diabetology201514:3

https://doi.org/10.1186/s12933-015-0175-6

Received: 12 October 2014

Accepted: 3 January 2015

Published: 13 January 2015

Abstract

Background

Hypoadiponectinemia is a well-known state associated with metabolic syndrome (MetS) and insulin resistance (IR). Recently aldosterone has been highly associated with high blood pressure, and may thus be a possible biomarker for MetS and IR. In this study, we investigate the association of aldosterone with MetS and IR, and compare it with that of adiponectin.

Methods

In this cross-sectional study, we recruited 556 women receiving physical examinations at a general hospital in central Taiwan. At the time of examination, we collected data on various demographic and physical characteristics and measured blood levels of aldosterone, adiponectin and a variety of metabolic factors. Multiple linear regression analysis was performed using adiponectin or aldosterone as the dependent variables.

Results

We found an inverse correlation between blood adiponectin and aldosterone (γ = −0.11, P = 0.009). Adiponectin levels were lower and aldosterone levels higher in women with MetS that those without (8.1 ± 0.4 vs. 11.5 ± 0.2 μg/mL, P < 0.001 and 691 ± 50 vs. 560 ± 11 pmol/L, P = 0.013, respectively), as they were in women with and without IR (adiponectin 10.4 ± 0.5 vs. 11.3 ± 0.2 μg/mL, P = 0.003 and aldosterone 635 ± 31 vs. 560 ± 11 pmol/L, P = 0.022). Although aldosterone was significantly related to body fat %, fasting plasma glucose and serum creatinine levels, the relationship between adiponectin and aldosterone was not obvious after adjustment in the multivariate analysis.

Conclusion

Although aldosterone was related to metabolic factors, including body fat % and fasting plasma glucose in our female subjects, the relationship between aldosterone and adiponectin remains unclear.

Keywords

AldosteroneMetabolic syndromeAdiponectinAdiposityGlucose

Background

Adiponectin has been found at lower blood levels in patients with metabolic syndrome (MetS) and its related co-morbidities, including obesity, type 2 diabetes mellitus (DM), dyslipidemia and hypertension [1-4]. In fact, hypoadiponectinemia may be one of the most important biomarkers for the MetS and obesity-induced insulin resistance (IR) [5,6]. Recently, activation of the renin-angiotensin-aldosterone system (RAAS) has been found to possibly play a role in the pathogenesis of obesity-related hypertension [7]. Two clinical trials have reported that blocking RAAS by either angiotensin converting enzyme inhibitors (ACEI) or angiotensin 2 receptor 1 blockers (ARB) can reduce the incidence of new-onset DM and the studies suggested that this reduction may have been a result of improvement in insulin sensitivity [8,9]. Treatment with ACEI or ARB has also been found to increase blood level of adiponectin in patients with hypertension [10,11].

Both animal and human studies have suggested that RAAS may play a role in MetS [12,13]. Previous several studies of people with high blood levels of aldosterone found a close assocation between primary aldosteronism and insulin resistance [14,15] as well as between lower blood adiponectin levels [16] and a higher prevalence of MetS [17,18], and suggested that aldosterone may also serve as a biomarker for MetS and IR [19,20]. Such an association has in fact been observed in two German populations [21].

The RAAS might also be a potential mediator of adiponectin activity [22]. Compared to men, women have been found to have higher blood levels of adiponectin [23] and aldosterone [24]. Despite these findings, the relationship between these two hormones in MetS and IR remain unclear. In an effort to better clarify their relationship, we surveyed 556 women in a routine health checkup and analyzed their blood levels of aldosterone in relation to MetS, IR and related co-morbidities, and compared the results with those for adiponectin.

Methods

Subjects

A total of 556 females who underwent a general health examination at Buddhist Dalin Tzu Chi Hospital in southern Taiwan between August 2009 and June 2012 were included in this study. Although we recruited male subjects, there were not enough to conduct a statistically powerful study of that gender number. Furthermore, because androgen has been shown to decrease adiponectin levels [25], their exclusion from the study may also be justified from this standpoint. In addition, subjects with current malignancy, infections, such as tuberculosis, or major organ failure, such as heart failure, liver cirrhosis and uremia were also excluded. Written informed consent was obtained from all subjects. This study was approved by the Institutional Review Board of the Buddhist Dalin Tzu Chi Hospital (No. B09801018-1 and B09901018). Demographic data, including age, gender, education levels, life style, and brief medical history, were collected. Anthropometric data, including body weight, body height and waist circumference, were measured. Seventy-seven subjects met the modified National Cholesterol Education Program definition of metabolic syndrome for Asians: (1) fasting glucose level > 5.55 mmol/L (100 mg/dL) or known diabetes with anti-diabetic treatment, (2) blood pressure > 130/85 mmHg or known hypertension with anti-hypertensive treatment, (3) fasting serum triglyceride level ≥1.70 mmol/L (150 mg/dL), (4) fasting HDL-C level < 1.30 mmol/L (50 mg/dL), and (5) waist circumference ≥80 cm. Body fat percentage was measured using a Body Composition Analyzer (Model TBF-410, Tanita Corporation, Tokyo, Japan). Sitting blood pressure was measured by an auto blood pressure machine (ProCare 100, GE Medical System Information Technologies, Inc., Piscataway, NJ, USA).

Laboratory tests

The tests of the overnight fasting blood samples, including those for lipids, sugar, blood cell counts and other biochemical items, were assayed by an auto-analyzer (Sysmex XE-2100 Blood Cell Analyzer, Kobe, Japan). The human insulin ELISA kit (BioSource Europe S.A., Nivelles, Belgium) was used for the insulin assay. The homeostasis model of assessment (HOMA) was used to evaluate insulin resistance [26], which was defined as the HOMA-IR of the highest quartile (≥1.864 in this study). The human adiponectin ELISA kit (B-Bridge International, Inc., Mountain View, CA, USA) was used for adiponectin assay. Aldosterone was measured using a radioimmunoassay kit following the manufacturer’s instructions (Adaltis Italia S.P.A., Bologna, Italy).

Statistical analysis

The data were presented as means ± S.D. or S.E.M. Student’s t-test was used to test the difference of means between two groups. Pearson correlation analysis was performed to evaluate the correlation between two variables. Multiple linear regression analysis was performed using adiponectin or aldosterone as the dependent variables and the indicated factors as the independent variables. In the stepwise variable selection procedure, both the significance levels for entry and stay in the data set were set at 0.15. The variables considered in the selection procedure are listed in Table 1, and the best candidate final regression model was then identified based on knowledge derived from the literature. Goodness-of-fit measures, including the coefficient of determination R 2, as well as statistical tools for regression diagnostics, such as residual analysis, detection of influential cases, and checking for multi-collinearity, were applied to discover model or data problems. A p value < 0.05 was considered significant. The statistical analysis was performed using STATA version 11.2 (Stata Corp LP, College Station, TX, USA) and the R 2.15.1 (Free Software Foundation, Inc., Boston, MA, USA) software.
Table 1

Basic characteristics of the 556 women and their correlations with adiponectin and aldosterone

  

Correlation with Adiponectin

Correlation with Aldosterone

Variables

Mean ±  S.D.

Γ

P =

Γ

P =

Age (years)

54.4 ± 9.8

0.09

0.032

−0.06

0.195

Height (cm)

155.4 ± 5.6

−0.01

0.805

−0.04

0.918

Weight (kg)

55.7 ± 7.8

−0.25

<0.001

0.07

0.105

BMI (kg/m 2 )

23.0 ± 3.1

−0.25

<0.001

0.07

0.081

Waist (cm)

72.8 ± 7.2

−0.27

<0.001

0.04

0.410

Body fat (%)

29.0 ± 5.9

−0.29

<0.001

0.19

<0.001

SBP (mmHg)

123.3 ± 19.7

0.06

0.155

0.02

0.680

DBP (mmHg)

71.0 ± 11.3

0.09

0.839

0.07

0.128

AC glucose (mM)

5.0 ± 1.0

−0.15

<0.001

0.20

<0.001

Fasting insulin (IU/mL)

6.3 ± 5.2

−0.10

0.021

0.09

0.034

HOMA-IR

1.4 ± 1.3

−0.13

0.002

0.15

<0.001

TG (mM)

1.2 ± 0.7

−0.25

<0.001

0.09

0.037

T-Chol (mM)

4.8 ± 0.9

0.04

0.365

0.13

0.003

LDL-C (mM)

3.1 ± 0.8

−0.07

0.115

0.11

0.009

HDL-C (mM)

1.5 ± 0.4

0.41

<0.001

−0.03

0.462

BUN (mM)

4.6 ± 1.5

0.04

0.389

0.12

0.006

CRE (μmol/L)

52.1 ± 14.1

0.05

0.246

0.19

<0.001

UA (μmol/L)

279.6 ± 71.4

−0.13

0.003

0.14

0.001

Adiponectin (μg/mL)

11.0 ± 4.9

-

-

−0.11

0.009

Aldosterone (pmol/L)

577.0 ± 280.2

−0.11

0.009

-

-

Abbreviations: BMI Body mass index, SBP Systolic blood pressure, DBP Diastolic blood pressure, AC glucose Fasting plasma glucose, fasting insulin Fasting serum insulin, HOMA-IR Insulin resistance index by homeostasis assessment model, mM mmol/L, TG Triglycerides, T-Chol Total cholesterol, LDL-C Low-density lipoprotein cholesterol, HDL-C High-density lipoprotein cholesterol, BUN Blood urea nitrogen, CRE Creatinine, UA Uric acid. Those p values < 0.05 were in bold form.

Results

As can been seen in Table 1, a summary of basic characteristics, we recruited 556 women. One hundred twenty-nine (23.2%) had a BMI ≥ 25 kg/m2 and seventy-nine (14.2%) a waist circumference ≥ 80 cm. Sixty-seven (12.1%) had either a fasting plasma glucose ≥ 5.55 mmol/L (100 mg/dL) or a previous diagnosis of diabetes. Twenty-eight (5.0%) were taking anti-diabetics medications and 89 (16.0%) anti-hypertension medications. Blood adiponectin levels correlated significantly with age, body weight, body mass index (BMI), waist circumference (WC), body fat percentage (%), fasting plasma glucose and insulin, and insulin resistance index (HOMA-IR), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and uric acids (UA) (Table 1). Plasma adiponectin levels correlated negatively with aldosterone levels (γ = −0.11, p = 0.009).

Aldosterone levels correlated positively only with body fat %, less that found for adiponectin, while correlation coefficients of adiponectin with BMI, WC and body fat % were quite comparable those of aldosterone (Table 1). In addition, like adiponectin, aldosterone was significantly correlated with fasting plasma glucose, fasting insulin and HOMA-IR, with magnitudes of the correlation about the same (Table 1). Although aldosterone was significantly correlated with TG, it had a much smaller γ than adiponectin. Nevertheless, it was significantly correlated with total cholesterol (T-Chol) and low-density lipoprotein cholesterol (LDL-C), but not HDL-C (Table 1). Finally, aldosterone concentrations were also correlated with uric acid, blood urea nitrogen and creatinine (Table 1).

The subjects were categorized into those with metabolic syndrome (MetS) and non-MetS groups (Table 2). Adiponectin levels in those with MetS (n = 77, 13.8%) were about around thirty percent lower (mean ± SEM: 8.1 ± 0.4 vs. 11.5 ± 0.2 μg/mL, p < 0.001, Figure 1A). Those meeting none, 1, 2 and 3 and more of the criteria for MetS had blood adiponectin levels of 12.1 ± 0.3, 11.5 ± 0.4, 10.2 ± 0.4 and 8.1 ± 0.4 μg/mL, respectively (mean ± SEM., p for trend = 0.030, Figure 1A), while they had about 19% higher levels of aldosterone (mean ± SEM: 691 ± 50 vs. 560 ± 11 pmol/L, p = 0.013 with unequal variances, Figure 1B). The subjects meeting none, 1, 2 and 3 and more criteria for MetS had blood aldosterone levels of 574 ± 17, 558 ± 17, 530 ± 25 and 694 ± 50 pmol/L, respectively (mean ± SEM., p for trend = 0.410, Figure 1B).
Table 2

The adiponectin and aldosterone levels in 556 women belong to various groups

 

n

Adiponectin (μg /mL)

Aldosterone (pmol/L)

Presence of criteria

Yes/No

Yes

No

P=

Yes

No

P=

Waist ≥ 80 cm

79/477

8.9 ± 0.5

11.4 ± 0.2

<0.001

535 ± 28

585 ± 14

0.141

Body fat30%

215/339

9.9 ± 0.3

11.8 ± 0.2

<0.001

616 ± 22

555 ± 14

0.016

IFG + diabetes

67/489

8.6 ± 0.5

11.4 ± 0.2

<0.001

671 ± 58

566 ± 11

0.081

SBP > 130 or DBP > 85 mmHg or hypertension

219/337

11.1 ± 0.4

11.0 ± 0.3

0.990

605 ± 22

560 ± 14

0.096

TG ≥ 1.7 Mm (150 mg/dL)

88/468

9.0 ± 0.4

11.4 ± 0.2

<0.001

644 ± 33

566 ± 14

0.035

HDL-C <1.3 Mm (50 mg/dL)

179/377

8.9 ± 0.3

12.1 ± 0.3

<0.001

602 ± 25

566 ± 14

0.219

Insulin resistance

139/416

10.4 ± 0.5

11.3 ± 0.2

0.003

635 ± 31

560 ± 11

0.022

Metabolism syndrome

77/479

8.1 ± 0.4

11.5 ± 0.2

<0.001

691 ± 50

560 ± 11

0.013

*The abbreviations are the same as those in Table 1.

*The values were expressed as Means ± SEM. *Those p values < 0.05 were in bold form.

*Two missing for FAT % and one missing for HOMA-IR.

*IFG: impaired fasting glucose: AC glucose ≥ 5.55 mM.

*Insulin resistance was defined as HOMA-IR > higher quartile (1.864 in our study).

Figure 1

The blood (A) adiponectin levels (Mean ± SEM) and (B) aldosterone levels (Mean ± SEM) in subjects with or without MetS or by the number of the MetS criteria met.

We also categorized subjects based on the various components of MetS, including central obesity, fasting glucose, triglycerides, HDL-C levels, and hypertension and insulin resistance markers (Table 2). We found a significant difference in adiponectin and aldosterone levels in centrally obese subjects only. Compared to those with impaired fasting glucose and diabetes, those with normal fasting glucose had significantly higher adiponectin levels and borderline lower aldosterone concentrations. Those with lower fasting plasma triglycerides had significantly higher adiponectin concentrations, but lower aldosterone concentrations, while those with higher HDL-C levels only had higher adiponectin levels, but not lower aldosterone levels. We found no differences in blood adiponectin and aldosterone concentrations between subjects with hypertension (SBP > 130 mmHg, DBP > 85 mmHg, or hypertension) and those with lower blood pressure. Insulin resistance was defined in subjects belonging to the highest HOMA-IR quartile. This group was found to have lower adiponectin levels but higher aldosterone levels (Table 2).

Based on our linear regression analysis, there was a negative association between adiponectin and aldosterone with borderline statistical significance after adjusting for several variables (Table 3). As expected, a larger waist circumference, impaired fasting glucose and diabetes were negatively related to blood adiponectin (Table 3). In contrast, age and HDL-C levels were positively associated with adiponectin levels. Using aldosterone as the dependent variable, we found body fat %, fasting plasma glucose and serum creatinine levels to be independently associated with blood aldosterone levels after adjustment (Table 3), though the relationship between adiponectin and aldosterone was not demonstrated in this model.
Table 3

Multiple linear regression analyses of the association of adiponectin and aldosterone using the stepwise variable selection procedure

 

Adiponectin

Aldosterone

Covariate

β ± SE

P=

β ± SE

P=

Age (per 5 years)

0.445 ± 0.106

<0.001

−7.542 ± 2.218

0.001

Waist (per 10 cm)

−1.418 ± 0.283

<0.001

-

-

Body fat (per 5%)

-

-

14.329 ± 3.702

<0.001

SBP (per 10 mmHg)

0.236 ± 0.103

0.023

-

-

IFG + DM (yes vs. no)

−1.812 ± 0.597

0.003

-

-

AC sugar (mM)

-

-

0.487 ± 0.124

<0.001

HDL-C (mM)

4.512 ± 0.505

<0.001

-

-

CRE (per μmol/L)

-

-

0.039 ± 0.008

<0.001

Adiponectin (μg/mL)

-

-

−0.019 ± 0.025

0.436

Aldosterone (per 100 pmol/L)

−0.124 ± .0.065

0.059

-

-

R 2

0.239

 

0.104

 

The abbreviations are the same as those in Table 1. Those p values < 0.05 were in bold form.

In order take into account possible confounding by medications being taken by the subjects, we further subcategorized our 556 subjects into whether they were taking anti-diabetic medications (n = 28) and anti-hypertension medications (89). We included these drugs as independent variables during the stepwise linear regression and found that they did not significantly affect our results. Additionally, we also tried excluding these subjects from our analysis and found our results to remain unchanged.

Discussion

In this study we observed a rise in blood aldosterone levels along with a fall in blood adiponectin levels in the subjects with MetS and IR, though there was no strong independent association between these two factors. Adiponectin appeared to decrease along with the presence each MetS criterion met in our subjects, whereas aldosterone levels were only significantly higher in those subjects with MetS, i.e., those meeting three or more the criteria.

Aldosterone and aldosterone vs. body fat

The links we found between adiponectin and greater waist circumference, impaired fasting glucose and diabetes were expected, because adiponectin is mainly synthesized and secreted by adipose tissue [27,28]. Adiponectin has also been found to enhance glucose utilization [29]. However, we also found a link between aldosterone and body fat, which is consistent with findings from two previous studies [20,30]. One recent study investigating gene expression of the steroidogenic enzymes in human adipose tissue has suggested that de novo biosynthesis of aldosterone in adipose tissue is not possible due the lack of key enzymes, such as aldosterone synthase [31]. However, human adipose tissue has been found to express angiotensinogen and ACE [32,33]. Therefore, the link we found between aldosterone and body fat may be at least in part a result effect of angiotensin, though further investigations are needed to fully define the exact mechanism behind this link between the two.

Aldosterone and insulin resistance

Blood aldosterone levels showed a significant correlation with the IR index obtained by HOMA in the current study, similar to our results found for adiponectin. The current theories regarding the effects of aldosterone on glucose metabolism primarily focus on IR induced by inflammation, oxidative stress, hypokalemia and disturbance of insulin signaling and hepatic gluconeogenesis [20,34]. However, after detailed analysis of the adipose tissues from subjects with primary aldosteronism, Urbanet et al. concluded that IR in primary aldosteronism might occur in body compartments other than the adipose tissue [14]. Aldosterone may affect glucose metabolism in non-adipose tissues, including the islet β-cell function [34,35]. Some conditions, like obstructive sleep apnea-hypopnea syndrome (OSAHS) have been associated with metabolic syndrome [36]. Barceló et al. found a link between sleep apnea and aldosterone levels and reported those levels to be reduced by continuous positive airway pressure (CPAP) therapy after 12 months of treatment [37]. Kamide, in a cell culture study, reported that insulin increased the expression of angiotensinogen and angiotensin II [38], thus it may be possible that cardiovascular events in subjects with metabolic syndrome could be reduced with the use of agents that block RAAS. Cherney et al. reported that treatment with empaglifozin, a sodium glucose cotransport-2 (SGLT2) inhibitor, resulted in a decline in arterial stiffness in young subjects with type 1 diabetes and that the treatment induced a modest increase in plasma aldosterone levels [39]. The authors of that study proposed that these results could be related to the fact that SGLT2 inhibitor can cause a loss in body weight loss and a decrease in insulin secretion. Remírez et al. found eplerenone, an aldosterone antagonist, able to decrease hyperlipidemia, insulin resistance, myocardial free fatty acid uptake, and the accumulation of reactive oxygen species in an animal model [40]. However, the exact mechanism through which aldosterone modulates glucose tolerance and mediates the effects of MetS remains elusive, and thus merits further investigation.

Negative relationship between adiponectin and aldosterone

The results of our regression model show a negative relationship between adiponectin and aldosterone, although this finding was of borderline significance. Aldosterone plays important roles in blood pressure regulation, and an inverse relationship between adiponectin and blood pressure has been reported previously in a study which also found that human adipocytes produced mineralocorticoid-stimulating factors that increased adrenal aldosterone secretion [41]. Increased aldosterone levels might then suppress expression of adiponectin protein through the mineralocorticoid receptor, as well as the glucocorticoid receptor. We postulate that increased adiposity or obesity directly decreases adiponectin synthesis in adipose tissue, and indirectly increases aldosterone production from the adrenal gland, probably secondary to increased angiotensin production from the adipose tissues. The results of the current study suggest that hypoadiponectinemia and hyperaldosteronism may work together to contribute to the development of glucose intolerance.

Limitation

This study has some limitations. One limitation is that it was an association study, and thus the cause-effect relationships cannot be inferred. Another limitation is that we used only women as study subjects. The observations reported in this study might thus not be generalized to men.

Conclusions

Higher blood aldosterone levels and lower blood adiponectin levels were found in the female subjects with MetS and IR. Aldosterone levels were independently related to body fat % and fasting plasma glucose. However, we found no independent relationship between aldosterone and adiponectin after adjustment of various anthropometric and metabolic factors.

Abbreviations

AECI: 

Angiotensin converting enzyme inhibitors

ARB: 

Angiotensin 2 receptor 1 blockers

CPAP: 

Continuous positive airway pressure

BMI: 

Body mass index

DM: 

Diabetes mellitus

HDL-C: 

High-density lipoprotein cholesterol

HOMA: 

Homeostasis model of assessment

HOMA-IR: 

Homeostasis model of assessment insulin resistance index

IR: 

Insulin resistance

LDL-C: 

Low-density lipoprotein cholesterol

mM: 

mmol/L

MetS: 

Metabolic syndrome

OSAHS: 

Obstructive sleep apnea-hypopnea syndrome

RAAS: 

Renin-angiotensin-aldosterone system

SGLT2: 

Sodium glucose cotransport-2

T-Chol: 

Total cholesterol

TG: 

Triglycerides

UA: 

Uric acid

WC: 

Waist circumference

Declarations

Acknowledgements

JKC received research grants from Buddhist Dalin Tzu Chi Hospital (DTCRD 96–13, 97–18, and 98 (2)-07) and WSY received support from the Research Supportive Fund from the National Taiwan University Hospital (MG151).

Authors’ Affiliations

(1)
Department of Family Medicine, Buddhist Dalin Tzu Chi Hospital
(2)
Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University
(3)
Graduate Institute of Epidemiology, College of Public Health, National Taiwan University
(4)
Departments of Internal Medicine, National Taiwan University Hospital
(5)
Family Medicine, National Taiwan University Hospital

References

  1. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001;86(8):3815–9.PubMedView ArticleGoogle Scholar
  2. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res. 2002;10(11):1104–10.PubMedView ArticleGoogle Scholar
  3. Huang KC, Chen CL, Chuang LM, Ho SR, Tai TY, Yang WS. Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. J Clin Endocrinol Metab. 2003;88(9):4130–4.PubMedView ArticleGoogle Scholar
  4. Chang LC, Huang KC, Wu YW, Kao HL, Chen CL, Lai LP, et al. The clinical implications of blood adiponectin in cardiometabolic disorders. J Formos Med Assoc. 2009;108(5):353–66.PubMedView ArticleGoogle Scholar
  5. Lu JY, Huang KC, Chang LC, Huang YS, Chi YC, Su TC, et al. Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond. J Biomed Sci. 2008;15(5):565–76.PubMedView ArticleGoogle Scholar
  6. Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrom, diabetes, and coronary disease? Cardiovasc Diabetol. 2014;13:103.PubMed CentralPubMedView ArticleGoogle Scholar
  7. Bogaert YE, Linas S. The role of obesity in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2009;5(2):101–11.PubMedView ArticleGoogle Scholar
  8. Ostergren J. Renin-angiotensin-system blockade in the prevention of diabetes. Diabetes Res Clin Pract. 2007;76 Suppl 1:S13–21.PubMedView ArticleGoogle Scholar
  9. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens. 2004;22(12):2253–61.PubMedView ArticleGoogle Scholar
  10. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension. 2003;42(1):76–81.PubMedView ArticleGoogle Scholar
  11. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004;110(24):3687–92.PubMedView ArticleGoogle Scholar
  12. Yong QC, Thomas CM, Seqqat R, Chandel N, Baker KM, Kumar R. Angiotensin type 1a receptor-deficient mice develop diabetes-induced cardiac dysfunction, which is prevented by renin-andiotensin system inhibitors. Cardiovasc Diabetol. 2013;12:169.PubMed CentralPubMedView ArticleGoogle Scholar
  13. Ramachandran V, Ismail P, Stanslas J, Shamsudin N. Analysis of renin-angiotensin aldosterone system gene polymorphisms in malaysian essential hypertensive and type 2 diabetic subjects. Cardiovasc Diabetol. 2009;8:11.PubMed CentralPubMedView ArticleGoogle Scholar
  14. Urbanet R, Pilon C, Calcagno A, Peschechera A, Hubert EL, Giacchetti G, et al. Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism. J Clin Endocrinol Metab. 2010;95(8):4037–42.PubMedView ArticleGoogle Scholar
  15. Widimský Jr J, Sindelka G, Haas T, Prázný M, Hilgertová J, Skrha J. Impaired insulin action in primary hyperaldosteronism. Physiol Res. 2000;49(2):241–4.PubMedGoogle Scholar
  16. Fallo F, Della Mea P, Sonino N, Bertello C, Ermani M, Vettor R, et al. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens. 2007;20(8):855–61.PubMedView ArticleGoogle Scholar
  17. Iacobellis G, Petramala L, Cotesta D, Pergolini M, Zinnamosca L, Cianci R, et al. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J Clin Endocrinol Metab. 2010;95(5):2391–8.PubMedView ArticleGoogle Scholar
  18. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91(2):454–9.PubMedView ArticleGoogle Scholar
  19. Sindelka G, Widimský Jr J, Haas T, Prázný M, Hilgertová J, Skrha J. Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Exp Clin Endocrinol Diabetes. 2000;108(1):21–5.PubMedGoogle Scholar
  20. Briet M, Schiffrin EL. The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep. 2011;13(2):163–72.PubMedView ArticleGoogle Scholar
  21. Hannemann A, Meisinger C, Bidlingmaier M, Döring A, Thorand B, Heier M, et al. Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur J Endocrinol. 2011;164(5):751–8.PubMedView ArticleGoogle Scholar
  22. Flynn C, Bakris GL. Interaction between adiponectin and aldosterone. Cardiorenal Med. 2011;1(2):96–101.PubMed CentralPubMedView ArticleGoogle Scholar
  23. Newbern D, Gumus Balikcioglu P, Balikcioglu M, Bain J, Muehlbauer M, Stevens R, et al. Sex differeneces in biomarkers associated with insulin resistance in obese adolescents: metabolic profiling and principal components analysis. J Clin Endocrinol Metab. 2014;9:jc20142080 [Epub ahead of print].Google Scholar
  24. Ferrario CM, Jessup JA, Smith RD. Hemodynamic and hormonal patterns of untreated essential hypertension in men and women. Ther Adv Cardiovasc Dis. 2013;7(6):293–305.PubMed CentralPubMedView ArticleGoogle Scholar
  25. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes. 2002;51(9):2734–41.PubMedView ArticleGoogle Scholar
  26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.PubMedView ArticleGoogle Scholar
  27. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271(18):10697–703.PubMedView ArticleGoogle Scholar
  28. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996;221(2):286–9.PubMedView ArticleGoogle Scholar
  29. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288–95.PubMedView ArticleGoogle Scholar
  30. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med. 1981;304(16):930–3.PubMedView ArticleGoogle Scholar
  31. MacKenzie SM, Huda SS, Sattar N, Fraser R, Connell JM, Davies E. Depot-specific steroidogenic gene transcription in human adipose tissue. Clin Endocrinol (Oxf). 2008;69(6):848–54.View ArticleGoogle Scholar
  32. Jonsson JR, Game PA, Head RJ, Frewin DB. The expression and localisation of the angiotensin-converting enzyme mRNA in human adipose tissue. Blood Press. 1994;3(1–2):72–5.PubMedView ArticleGoogle Scholar
  33. Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab. 1998;83(11):3925–9.PubMedGoogle Scholar
  34. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150(11):776–83.PubMed CentralPubMedView ArticleGoogle Scholar
  35. Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA, et al. A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens. 2007;25(10):2125–30.PubMedView ArticleGoogle Scholar
  36. Basoglu OK, Sarac F, Sarac S, Uluer H, Yilmaz C. Metabolic syndrome, insulin resistance, fibrinogen, homocysteine, leptin, and C-reactive protein in obese patients with obstructive sleep apnea syndrome. Ann Thorac Med. 2011;6(3):120–5.PubMed CentralPubMedView ArticleGoogle Scholar
  37. Barceló A, Piérola J, Esquinas C, de la Peña M, Arqué M, Alonso-Fernández A, et al. Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatment. PLoS One. 2014;9(1):e84362.PubMed CentralPubMedView ArticleGoogle Scholar
  38. Kamide K. Role of renin-angiotensin-aldosterone system in metabolic syndrome and obesity-related hypertension. Curr Hypertens Rev. 2014. [Epub ahead of print].Google Scholar
  39. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, et al. The effect of empaglifolzin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28.PubMed CentralPubMedView ArticleGoogle Scholar
  40. Ramírez E, Klett-Mingo M, Ares-Carrasco S, Picatoste B, Ferrarini A, Rupérez FJ, et al. Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. Cardiovasc Diabetol. 2013;12:172.PubMed CentralPubMedView ArticleGoogle Scholar
  41. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100(24):14211–6.PubMed CentralPubMedView ArticleGoogle Scholar

Copyright

© Chiang et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement